Mental health professionals' views and experiences of antipsychotic reduction and discontinuation

被引:28
作者
Cooper, Ruth E. [1 ]
Hanratty, Eanna [2 ]
Morant, Nicola [3 ]
Moncrieff, Joanna [2 ,3 ]
机构
[1] Queen Mary Univ London, Newham Ctr Mental Hlth, Unit Social & Community Psychiat, London, England
[2] North East London NHS Fdn Trust, Goodmayes Hosp, Res & Dev Dept, Rainham, Essex, England
[3] UCL, Div Psychiat, London, England
来源
PLOS ONE | 2019年 / 14卷 / 06期
基金
美国国家卫生研究院;
关键词
REMITTED 1ST-EPISODE PSYCHOSIS; SHARED DECISION-MAKING; MAINTENANCE TREATMENT; SCHIZOPHRENIA; MEDICATION; DRUGS; CARE; MANAGEMENT; POWER; RISK;
D O I
10.1371/journal.pone.0218711
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background The widely established treatment for psychosis is long-term antipsychotic medication. However, many people stop taking this treatment, and request other options. There are also growing concerns about adverse effects, but currently no professional guidelines to support reducing or stopping these drugs. The views and experiences of individual mental health professionals around reducing and stopping antipsychotics are therefore crucial in treatment decisions. Methods We conducted 7 focus groups with prescribing psychiatrists and other members of community-based statutory mental health services in London. Participants discussed their views about, experiences, and processes of antipsychotic reduction and discontinuation. Data were analysed using thematic analysis. Results Participants acknowledged that antipsychotics can have severe adverse effects. They were generally supportive of trying to reduce these drugs to the lowest effective dose, although stopping antipsychotics was less acceptable. Prior experiences of adverse events after reduction or discontinuation meant that both were approached with caution. Reduction was also reported to be hampered by organisational and knowledge barriers. Lack of resources, pressure to discharge, and poor continuity of care were seen as organisational barriers. Knowledge barriers included inadequate evidence about who might be best suited to reduction, and lack of guidance about how this could be done safely. This meant that reduction was often prompted by patients, and sometimes actively discouraged, and stability with maintenance treatment was often favoured. Conclusions Concerns about risk and other barriers means that clinicians are often reluctant to implement reduction or discontinuation of antipsychotic medication. In order to increase the treatment options available to service users, more research and guidance on how to minimise the risks of antipsychotic reduction and discontinuation is required to enable clinicians to engage more constructively with service users requests, offering people more choice and control in managing their mental health condition.
引用
收藏
页数:18
相关论文
共 52 条
  • [1] [Anonymous], 2014, PSYCH SCH AD PREV MA
  • [2] [Anonymous], 2012, The Abandoned Illness A Report By The Schizophrenia Commission
  • [3] Baker E., 2013, Advances in psychiatric treatment, V19, P2, DOI [10.1192/apt.bp.110.008342, DOI 10.1192/APT.BP.110.008342]
  • [4] Braun V., 2013, Successful Qualitative Research: A Practical Guide for Beginners, P19
  • [5] Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [DOI 10.1191/1478088706QP063OA, 10.1191/1478088706qp063oa]
  • [6] Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial
    Chen, Eric Y. H.
    Hui, Christy L. M.
    Lam, May M. L.
    Chiu, Cindy P. Y.
    Law, C. W.
    Chung, Dicky W. S.
    Tso, Steve
    Pang, Edwin P. F.
    Chan, K. T.
    Wong, Y. C.
    Mo, Flora Y. M.
    Chan, Kathy P. M.
    Yao, T. J.
    Hung, S. F.
    Honer, William G.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2010, 341
  • [7] Cooper RE, SCHIZOPHR RES
  • [8] Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
    De Hert, Marc
    Detraux, Johan
    van Winkel, Ruud
    Yu, Weiping
    Correll, Christoph U.
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2012, 8 (02) : 114 - 126
  • [9] GILBERT PL, 1995, ARCH GEN PSYCHIAT, V52, P173
  • [10] Involving patients in decisions during psychiatric consultations
    Goss, Claudia
    Moretti, Francesca
    Mazzi, Maria Angela
    Del Piccolo, Lidia
    Rimondini, Michela
    Zimmermann, Christa
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 2008, 193 (05) : 416 - 421